Bipolar Disorder Treatment Denied by Insurance: Your Appeal Rights

Bipolar disorder requires precise, often complex treatment — and insurance companies deny claims for it at alarming rates. Whether your insurer rejected a mood stabilizer, refused to cover an atypical antipsychotic, or cut short an inpatient psychiatric admission during a manic or depressive episode, these denials are frequently illegal under federal law and absolutely worth fighting.

The Federal Law Most Insurers Hope You Don't Know About

The Mental Health Parity and Addiction Equity Act (MHPAEA) is one of the most powerful tools available to mental health patients. It requires that insurance plans covering mental health and substance use disorders apply the same coverage criteria, limits, and Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization requirements that they apply to comparable medical and surgical conditions.

In practice, this means: if your plan covers a hospitalization for a cardiac event without requiring pre-authorization that meets a stringent inpatient criteria checklist, it cannot apply a more restrictive standard to a psychiatric hospitalization. If your plan covers brand-name medications for physical conditions without step therapy, it cannot require you to fail multiple generic alternatives before covering a psychiatric medication your doctor prescribed.

MHPAEA violations are common and often documented only through comparison analysis. Your insurer must provide a detailed written disclosure — called a Nonquantitative Treatment Limitation (NQTL) analysis — explaining how they apply criteria for mental health versus medical/surgical benefits. Request this document in writing.

Common Bipolar Disorder Denial Scenarios

Mood Stabilizer Denials: Lithium remains a first-line agent, but when patients need alternatives — valproate, lamotrigine, carbamazepine — insurers may require step therapy or restrict access to specific formulations. Extended-release versions are often denied as "not medically necessary" despite documented tolerability advantages.

Atypical Antipsychotic Denials: Medications like quetiapine, aripiprazole, lurasidone, and cariprazine have FDA indications for bipolar disorder but face aggressive prior authorization barriers. Insurers may require failure of older, less-tolerated agents first, regardless of the patient's history or the prescribing psychiatrist's documented rationale.

Inpatient Admission Denials: Concurrent review denials — where an insurer approves admission but then refuses to authorize continued inpatient days — are a major problem in bipolar care. The insurer's internal reviewer may determine the patient is "stable enough" to discharge based on a chart review, overriding the treating psychiatrist's clinical judgment.

Residential and Intensive Outpatient Denials: Step-down from inpatient to residential or PHP (partial hospitalization program) is clinically standard for bipolar disorder, yet insurers frequently deny residential care as "not medically necessary" or apply criteria more stringent than those used for comparable medical conditions.

Building Your Appeal

Document the full treatment history. Prior treatment failures, hospitalizations, medication trials and their outcomes, and documentation of functional impairment all matter. The more complete the clinical picture, the harder it is for a utilization reviewer to dismiss the claim.

Invoke MHPAEA explicitly. Your appeal letter should state that the denial may constitute a parity violation and request the insurer's NQTL comparative analysis. This signals to the insurer that you understand your rights and are prepared to escalate.

Get your psychiatrist involved. A peer-to-peer review request — your psychiatrist speaking directly with the insurer's reviewing clinician — is one of the most effective tools available before a formal appeal is required. Ensure your psychiatrist is prepared to cite clinical criteria and respond to the specific stated denial reason.

Use the Level 3A inpatient criteria from InterQual or Milliman. Many insurers use these commercially licensed criteria sets for inpatient psychiatric admissions. Ask which criteria set your insurer uses, then ask your treatment team to document how those specific criteria are met.

External Independent Review: Complete Guide" class="auto-link">External review for inpatient denials. If your internal appeal is denied, request an independent external review. Under the ACA, external reviewers must be clinicians with relevant specialty expertise. For bipolar disorder inpatient denials, the external reviewer should be a psychiatrist — request confirmation of credentials.

Filing a Regulatory Complaint

If you believe your insurer violated MHPAEA, you can file a complaint simultaneously with:

• Your state insurance commissioner
• The U.S. Department of Labor (for ERISA employer-sponsored plans)
• Your state's mental health agency

The Substance Abuse and Mental Health Services Administration (SAMHSA) also publishes guidance on parity enforcement that is useful for documenting potential violations.

Fight Back With ClaimBack

Bipolar disorder is a serious, lifelong condition. You deserve treatment that works — and insurance coverage that the law requires. ClaimBack helps you build a structured, evidence-based appeal that invokes your actual legal rights.

Start your bipolar disorder insurance appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter That Gets Results
• What Is Medical Necessity — and How to Prove It to Your Insurer
• Common Reasons Insurance Claims Are Denied